The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by ...

On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...

"We're excited to achieve the first milestone of our collaboration with Merck and continue our work to improve biologic ...

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its ... the mid-point and sales around the lower half of ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

At the start of the month, the company spent $750 million to buy an early clinical-stage treatment that aims to treat a pair ...

Despite Summit's impressive data, Merck is still another biopharma company that's worth buying and holding for at least five ...